NeurologyWire

Valeant Commences Exchange Offer For Allergan

From Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30th proposal directly to Allergan stockholders. Under the terms of the offer, Allergan stockholders would be able to elect to exchange...

Read full article

Wednesday, July 30, 2014

Show last days of articles

FDA approves new oxycodone with abuse-deterrent properties

From NeurologyWire

On July 23 the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), a...Full story

Neuro researchers advocate for a shift in thinking for strok...

From NeurologyWire

With the advent of non-surgical modalities, stimulation of the brain has become a popular science and researchers must work to ensure systematic metho...Full story

RapidArc Radiosurgery More Efficient and Comparable in Quali...

From NeurologyWire

RapidArc Radiosurgery can be used to deliver treatments for multiple brain metastases that are substantially less time consuming and comparable in qua...Full story

Monday, July 28, 2014

NIH scientists find six new genetic risk factors for Parkins...

From NeurologyWire

Using data from over 18,000 patients, scientists have identified more than two dozen genetic risk factors involved in Parkinsons disease, including si...Full story

Friday, July 25, 2014

CDC Takes Inside Look at ALS

From NeurologyWire

The firstand to date the onlyeffort to estimate the national prevalence of amyotrophic lateral sclerosis in the United States has concluded, unsurpris...Full story

MS drug Plegridy receives European marketing approval

From NeurologyWire

The European Commission (EC) has granted marketing authorisation for Biogen Idec.'s Plegridy (peginterferon beta-1a) as a treatment for adults with re...Full story

Wednesday, July 23, 2014

Positive Topline Results for Phase III Epilepsy Drug

From NeurologyWire

UCB has announced positive topline results from its Phase III study with the epilepsy drug brivaracetam, which will provide the basis for its FDA fili...Full story

Tuesday, July 22, 2014

Sublingually delivered Parkinson's therapy moves to Phase II

From NeurologyWire

A sublingually delivered thin film strip to treat advanced Parkinson's will move to a Phase II clinical trial after FDA approval. The therapy, APL-130...Full story

Ibuprofen and Oxcarbazepine recalled for mislabeled packagin...

From NeurologyWire

American Health Packaging (AHP) issued a recall of Ibuprofen Tablets that may contain individual blistered doses labeled as Oxcarbazepine Tablets. The...Full story

Monday, July 21, 2014

Parkinson's trial begins Phase II

From NeurologyWire

Cynapsus Therapeutics says that a Phase II clinical studies for APL-130277 will commence immediately.Specifically, clinical study CTH-105 will be init...Full story

Friday, July 18, 2014

Dietary Fatty Acids May Reduce ALS

From NeurologyWire

Consumption of foods high in -3 PUFAs (omega-3 fatty acids) may help prevent or delay the onset of ALS, according to a new study in the July 16 issue ...Full story

Parkinson's drug commences phase 2

From NeurologyWire

Phase 2 clinical studies for APL-130277 will commence immediately, Cynapsus Therapeutics announced. Specifically, clinical study CTH-105 will be initi...Full story

Thursday, July 17, 2014

Stroke Incidence, Mortality Down Over 20+ Years

From NeurologyWire

In a multicenter cohort of black and white adults in US communities, stroke incidence and mortality rates decreased from 1987 to 2011. The decreases v...Full story

Alzheimer's drug crenezumab fails main goals

From NeurologyWire

The experimental drug crenezumab failed to improve thinking and memory in people with Alzheimers disease, but the results from two Phase II studies le...Full story

New MS Drug Enters Phase I

From NeurologyWire

Alkermes has initiated a phase 1 clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple ...Full story